1. Introduction
===============

The global epidemic of coronavirus disease 2019 (COVID-19) has presented a major threat to public health worldwide. COVID-19 is the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first isolated and identified in patients who were exposed at a seafood market in Wuhan City, Hubei Province, China on December 2019 (Zhu N et al., [@B95]). Similar to findings related to SARS-CoV (Drosten et al., [@B20]; Ksiazek et al., [@B41]) and Middle East respiratory syndrome coronavirus (MERS-CoV) (Zaki et al., [@B85]), SARS-CoV-2 is believed to cross species to initiate primary human infections; it is now spread primarily by human-to-human transmission. Although the case fatality rate of COVID-19 (estimated at 2%--3%) is lower than those of SARS (approximately 10%) and MERS (approximately 40%), the pandemic associated with COVID-19 has been far more severe. As of Mar. 15, 2020, SARS-CoV-2 has spread rapidly to 34 provinces and cities in China; infection has been reported in 144 countries/territories/areas across five continents (World Health Organization, [@B72]). The COVID-19 epidemic represents a substantial challenge for governments, individuals, and society as a whole.

This review summarizes the latest findings and expert consensus as it relates to the virology, immunology, epidemiology, clinical features, diagnosis, and management of COVID-19. Our aim is to provide the most up-to-date understanding of both the virus and the disease, as well as to provide ongoing guidance for its prevention, control, and management.

2. Virology and immunology
==========================

2.1. Structure of coronavirus
-----------------------------

There are four main subgroups of coronaviruses (α, β, γ, and δ). There are six members of the α coronavirus group, including human pathogens Cov-229E and CoV-HKU1. The β coronavirus group includes the human pathogens CoV-OC43, SARS-CoV, and MERS-CoV (King et al., [@B39]; Lefkowitz et al., [@B44]). SARS-CoV-2 is also a β coronavirus; the amino acid sequences within the seven conserved domains within the genomic open reading frame 1ab (ORF1ab) are 94.6% identical to that of the original SARS-CoV (Zhou P et al., [@B93]).

The coronavirus virion particle is typically round or multi-shaped. It measures 120--160 nm in diameter and includes a petal-shaped projection consisting of a triple Spike (S) protein, which is common a feature of the coronaviruses. The S protein mediates virus attachment and membrane fusion during infection (King et al., [@B39]). In addition to the characteristic S protein, coronavirus genomes generally encode three additional structural proteins, including the Membrane (M) protein, the Envelope (E) protein, and the Nucleocapsid (N) protein. The coronavirus M protein, 218 to 263 amino acids (aa), has an N-terminus modified by an *O-*or *N*-glycan and a hydrophilic C-terminal tail. The E protein, 74--109 aa, may be involved in promoting virulence; there are typically about 20 copies of this protein per virion. The coronavirus N protein, 349 to 470 aa, is an RNA-bound phosphorylated protein that facilitates appropriate folding of genomic RNA into the nucleocapsid (King et al., [@B39]).

2.2. Genomic characterization of SARS-CoV-2
-------------------------------------------

The SARS-CoV-2 virion has a diameter of 60--140 nm and a positive-sense, single-stranded 29 891 bp RNA genome (Zhou P et al., [@B93]). Genome sequence alignment has revealed a 79.5% sequence identity between SARS-CoV-2 and SARS-CoV and a remarkable 93.1% identity with the sequence of the RaTG12 virus isolated from a bat (*Rhinolophus affinis*) residing in Yunnan Province, China (Chan et al., [@B9]; Zhou P et al., [@B93]); these latter results suggest that SARS-CoV-2 may originate from a virus that is endemic in this bat species. Comparative genomic analysis primarily based on sequence inserts identified in the S protein of a coronavirus isolated from the pangolin (Order, Pholidota; Family, Manidae) suggested that these mammals were most likely the intermediate hosts for cross-species transmission (Liu et al., [@B51]; Zhang T et al., [@B87]).

A comprehensive analysis of the SARS-CoV-2 genome together with that of SARS-CoV revealed the presence of nearly thirty ORFs and two novel insertions (Cui HZ et al., [@B15]). The genome analyses of SARS-CoV and bat coronaviruses indicate that the sequences of *ORF6*, *ORF8*, and the *S* gene display a comparatively low degree of sequence conservation among coronaviruses in general. However, the genomes of *bat-SL-CoVZC45* (GenBank ID: MG772933), *bat-SL-CoVZXC21* (GenBank ID: MG772934) and *RaTG13* (GenBank ID: MN996532) viruses are overall quite similar to that of SARS-CoV-2, most notably with respect to *ORF8* (Chan et al., [@B10]; Chen LJ et al., [@B12]; Cui HZ et al., [@B15]). There are currently several characterized *ORF8* variants encoded by the SARS-CoV-2 genome (Ceraolo and Giorgi, [@B8]; Chan et al., [@B10]; Cui HZ et al., [@B15]; Dong et al., [@B19]; Zhou P et al., [@B93]). The full implications of these observations await further understanding of the function of *ORF8* within SARS-CoV-2. Likewise, the primary host source of SARS-CoV-2 should be confirmed in the near future.

2.3. Infectious characteristics of SARS-CoV-2 S protein
-------------------------------------------------------

Similar to what was ultimately found for SARS-CoV, the binding of SARS-CoV-2 S protein to its cell surface receptor, angiotensin converting enzyme 2 (ACE2), initiates viral entry into type II pneumocytes in the human lung (Gallagher and Buchmeier, [@B24]). As such, the S protein plays a central role in the initial transmission and ongoing infection of SARS-CoV-2. The coronavirus S protein includes two main domains: the S1 domain at the N-terminus of the protein mediates binding to ACE2 and the C-terminal S2 domain promotes fusion of the virus membrane with cellular membrane of the host cell (Hofmann and Pöhlmann, [@B32]; Li, [@B47]). The receptor-binding domain (RBD) is a subdomain of S1 that includes 424--494 aa. This motif comes into direct contact with the extracellular binding site on ACE2 known as the peptidase domain (PD) (Li et al., [@B48]; Wrapp et al., [@B73]). There are two cleavage sites in the S protein, arginines R667 and R797. The R667 site is at the division between S1 and S2 and cleavage at the R797 site results in the final S2 polypeptide (Millet and Whittaker, [@B56]). Numerous cellular proteases can cleave the S sequence at these two sites, including cathepsin L, trypsin, elastase, serine transmembrane proteases (TMPRSSs), and factor Xa, among others. Cleavage at both S protein sites is essential to promote entrances of SARS-CoV and SARS-CoV-2 into the host cell; the first is critical for S1 binding to ACE2 and the second is essential for membrane fusion (Li, [@B47]; Millet and Whittaker, [@B56]).

2.3.1 Binding motif in the S protein of SARS-CoV-2

The amino acid sequence of the SARS-CoV-2 S protein shares only limited homology with that of SARS-CoV; the degree of similarity is quite low within the S1 domain (64%) and comparatively high within the S2 domain (up to 90%). Within the S1 domain, the N-terminal region is overall less conserved (51%), while the C-terminal RBD subdomain has relatively high conservation (74%), thereby permitting interactions with the same cell surface receptor ACE2 (Jaimes et al., [@B35]). There are four to five distinct changes in amino acid sequence within the S1 RBD domain of SARS-CoV-2 compared to SARS-CoV. These amino acids include X442, F472, C479, and N487 that are included in the S protein sequence of SARS-CoV-2 (Zhou P et al., [@B93]). These changes within a critical motif in S1 RBD domain may serve to influence receptor-mediated binding and ultimately the transmissibility of the new coronavirus. Several groups have already explored this issue. For example, Wrapp et al. ([@B73]) found that binding of quantities as low as 15 nmol/L of the S1 domain of SARS-CoV-2 could be detected at the ACE2 using optical biosensing via surface plasmon resonance. These results suggest that the S protein of SARS-CoV-2 has a 10--20 fold higher affinity for this receptor than does that of SARS-CoV. Interestingly, in silico analysis of the interactions of ACE2 and the S protein of SARS-CoV-2 led to different conclusions (Huang and Herrmann, [@B34]; Lan et al., [@B43]), although these results remain to be confirmed by in vitro and in vivo experiments.

2.3.2 Effect of insertions within the S protein sequence on SARS-CoV-2 infectivity

SARS-CoV-2 is a highly transmissible coronavirus; evaluation of transmission rates suggests that this may be 3-and 10-fold higher than those of SARS-CoV and MERS, respectively (Jiang and Shi, [@B37]). The transmissibility of SARS-CoV-2 is directly associated with the sequence of the S protein, which includes one of the sequence insertions detected in the genome of SARS-CoV-2 (Heurich et al., [@B30]; Millet and Whittaker, [@B56]). A four-residue insertion has been found in the S protein directly adjacent to the cleavage site (Meng et al., [@B55]). TMPRSSs have been identified as contributing to both SARS-CoV and MERS-CoV infections; TMPRSS and TMPRSS11a can catalyze the cleavage of the S protein to S1 and S2 (or S2\') domains at the sites of both R667 and R797 residues (Heurich et al., [@B30]; Millet and Whittaker, [@B56]). In combination with R685, the four amino acids in the insertion, P681, R682, R683, and A684, can form an exposed loop; this will result in an increased sensitivity to proteases. The insert sequence has also generated a cleavage site for the protease, furin (Jaimes et al., [@B35]; Meng et al., [@B55]). Hoffmann et al. ([@B31]) and Meng et al. ([@B55]) confirmed that TMPRSS1 and TMPRSS2 may be the proteases activating S protein and then contributing to SARS-CoV-2 binding and cell entry. Furthermore, Jaimes et al. ([@B35]) and Walls et al. ([@B67]) reported that the loop formed by the inserted residues increased S protein susceptibility to protease-mediated cleavage, which facilitated SARS-CoV-2 infection. The insertion sequence is unique and has not been found in any other known coronaviruses, not even RaTG12 coronavirus from the bat (Jaimes et al., [@B35]; Zhou P et al., [@B93]).

2.4. Pathology and disease pathogenesis
---------------------------------------

An autopsy report of a 50-year old male patient revealed many details of the condition of the lungs of those suffering from the most critical forms of COVID-19. This patient died due to acute respiratory distress syndrome (ARDS) with features that included desquamation of pneumocytes, hyaline membrane formation, and interstitial inflammation and infiltration of large numbers of lymphocytes. Additionally, viral cytopathic-like changes, including multi-nucleated syncytial cells and atypical enlarged pneumocytes, were detected in the intra-alveolar spaces (Xu Z et al., [@B80]).

The pathogenesis of COVID-19 is largely unknown, but it may mimic SARS to some extent. The viral infection is cytopathic to human airway epithelial cells and alveolar cells as well. However, similar to what was observed in response to SARS-CoV, immune-mediated injury may play a critical role in the pathogenesis of COVID-19, notably among those who are critically ill due to severe disease. Viral infection of pneumocytes induces local inflammatory responses and promotes the release of cytokines, including transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, as well as numerous chemokines that serve to recruit circulating leukocytes (Razzaque and Taguchi, [@B61]). In severe forms of COVID-19, the ensuing inflammatory cascade may lead to a cytokine storm, as observed in a recent study that documented elevated serum cytokine levels, including IL-2, IL-7, IL-10, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein (MCP), and TNF-α (Huang et al., [@B33]). The cytokine storm is believed to be a key factor driving both ARDS and extra-pulmonary organ failure (Li and Xu, [@B46]).

Peripheral lymphopenia is commonly observed, notably in association with the more severe form of COVID-19. This observation may reflect functional compartmentalization due to the apparent recruitment of these cells into virus-infected lung tissue rather than any specific virus-mediated suppression (Xu Z et al., [@B80]). Despite reductions in the total number, there is clearly an increased proportion of activated HLA-DR^+^CD38^+^ T cells in peripheral blood. Similarly, there is an increase in the fraction of CCR4^+^CCR6^+^Th17 cells, a subgroup of CD4^+^ T cells with cytotoxic functions similar to those characterized for CD8^+^ T cells (Xu Z et al., [@B80]). As such, these primary data suggest a critical role for T cells in modulating the COVID-19-related lung inflammatory response, although mechanistic studies performed with appropriate animal models and human lung specimens will most certainly be needed to evaluate this issue further.

3. Epidemiology
===============

3.1. Basic links to the SARS-CoV-2 epidemic
-------------------------------------------

3.1.1 Source of infection

The infectious sources of SARS-CoV-2 are infected animal hosts and other humans. Bats are considered to be the most likely initial hosts of SARS-CoV-2, while pangolins may be the intermediate hosts. Likewise, both symptomatic and asymptomatic patients are known to be contagious. However, it is not clear how long virus shedding persists and how transmissibility might be altered during the natural history of the disease.

The Chinese Center for Disease Control and Prevention (CDC) analyzed environmental specimens and animal samples from Huanan Seafood Market and several other fresh markets in Wuhan, China. The results revealed that 94% of SARS-CoV-2 nucleic acid-positive samples (31/33 cases) came from the western part of the Huanan Seafood Market, which includes facilities that provide wild animals for purchase. Bats are natural hosts of many of the known coronaviruses (de Wit et al., [@B18]). As noted earlier, SARS-CoV-2 is a β coronavirus; sequence similarities between SARS-CoV-2 and β coronaviruses isolated from bat species can be as high as 89.0% (Zhu N et al., [@B95]) to 96.2% (Zhou P et al., [@B93]), which indicates that SARS-CoV-2 may be derived from a predecessor coronavirus endemic in bats. Moreover, comparative studies revealed that the similarity between the nucleic acid sequences of the genomes of SARS-CoV-2 and SARS-CoV reached 79.5%, notably 73.8%--74.9% at the two receptor domains, both of which share ACE2 as a common receptor (Zhou P et al., [@B93]; Zhu N et al., [@B95]). Interestingly, the genomes of SARS-CoV-2 and the bat coronaviruses also differ, with about 1100 bp nucleotide divergence (Zhou P et al., [@B93]). It is also critical to recognize that the major outbreak emerged during the winter when bats are hibernating. As such, the data suggest that there may be one or more intermediate hosts that link the bat coronaviruses to those transmitted to humans.

Results from a study by Ji et al. ([@B36]) suggested that the SARS-CoV-2 intermediate host might be snakes; however, this contention has been questioned by many experts, given that snakes are cold-blooded animals (Class, Reptilia) whereas the intermediate hosts of SARS and MERS, the civet and the camel, respectively, are both homeothermic. The study of Guo et al. ([@B28]), which featured deep learning algorithms, suggested that minks (Order, Carnivora) may serve as the potential intermediate host, but no experimental evidence was provided to support this hypothesis. The pangolin is currently considered to be the most likely among the candidate intermediate hosts. A research team from the South China Agricultural University (Guangzhou, China) has identified a coronavirus strain from pangolins, which has 99% sequence similarity with SARS-CoV-2 (Kong, [@B40]). The current leading hypothesis is that the bat-derived virus evolved to infect pangolins; after a series of mutations and recombination events, it has been transmitted to humans. However, the data from this research study have not been published yet. Meanwhile, Lam et al. ([@B42]) have identified a coronavirus strain in the Malay pangolin with a genome that was similar to that of SARS-CoV-2 at 85.5%--92.4%. Of note, the Malay pangolin GD/P1L and GD/P2S coronaviruses are closely related to SARS-CoV-2. These results suggest that the pangolin may be a long-term host of these pathogens. Furthermore, a team from the China Animal Health and Epidemiology Center (Qingdao, China) tested more than 4800 poultry and livestock samples, and ruled out the possibility that SARS-CoV-2 could have its origins in poultry or livestock (Zhao and Lv, [@B90]).

With the closure of the Huanan Seafood Market and animal trading markets in most regions of China, wild animals are no longer the main source of infection. Human subjects infected with SARS-CoV-2 are currently the main sources of ongoing infection (General Office of National Health Commission of the People's Republic of China, [@B26]; Huang et al., [@B33]). In particular, asymptomatic patients constitute an unpredictable and insidious transmission source that cannot be identified promptly. The unknown numbers of those with asymptomatic infection may explain why SARS-CoV-2 seems to be more contagious than SARS-CoV, the transmission of which is largely limited to symptomatic patient sources. The transmission capacity of asymptomatic patients has been supported by a recent study that revealed that the dynamics of virus shedding was indistinguishable in a comparison between asymptomatic and symptomatic individuals (Zou et al., [@B96]). This study also demonstrated that higher viral loads were a characteristic of the early stage of disease and were more readily detected from specimens on nasopharyngeal swabs than on oropharyngeal swabs. It is not at all clear at this time how long the capacity to transmit virus persists, but two independent studies reported that infected individuals can transmit virus during both the incubation (Rothe et al., [@B62]; Xu Z et al., [@B80]) and recovery periods (Rothe et al., [@B62]). These critical observations need to be confirmed in larger studies.

3.1.2 Routes of transmission

Respiratory droplet and contact transmission are the main transmission routes for person-to-person spread of SARS-CoV-2. Other potential routes include aerosol and fecal-oral transmissions, which have not yet been confirmed (General Office of National Health Commission of the People's Republic of China, [@B26]; Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, [@B64]).

Respiratory droplet transmission: Respiratory droplets are believed to be the predominant route of transmission, similar to that observed in other respiratory virus infections.

Contact transmission: Since SARS-CoV-2 was found to persist within the environment of infected individuals in Guangzhou, China (household surfaces, door handles, mobile phones, and such), it is not fairly certain that SARS-CoV-2 can also be transmitted through both direct and indirect contacts with virions (General Office of National Health Commission of the People's Republic of China, [@B26]). When susceptible individuals come into contact with virus-containing body fluids (sputum, saliva, feces) from humans or animals, SARS-CoV-2 can be transmitted through the oral cavity, nasal cavity, and other mucous membranes. Likewise, when susceptible individuals come into contact with body fluid-contaminated items, indirect transmission of SARS-CoV-2 can occur.

Aerosol transmission: Biological aerosol refers to droplets containing pathogens (viruses or bacteria) that are suspended in the air for a period of time and lose moisture; the remaining proteins and pathogens form droplet cores and they are able to transfer some distance along the air currents, resulting in potential long-distance transmission of disease. Patients with severe SARS-CoV-2 infection may shed virus to a greater degree during specific medical interventions (mask ventilation, non-invasive ventilation, and tracheal intubation); this can generate local aerosols, which put others in the environment at greater risk (Wax and Christian, [@B71]).

Fecal-oral and urinary transmission: Recently, the teams of Lan-juan LI and Nan-shan ZHONG isolated SARS-CoV-2 from the feces and urine of patients with COVID-19. These findings indicate that the virus can survive in the digestive tract and the urethra, and suggest that SARS-CoV-2 could be transmitted via the fecal-oral or urinary route (Fang, [@B22]; Xinhuanet, [@B76]). However, how the virus persists in feces and urine is currently under further investigation.

Mother-to-child transmission: On Feb. 6, 2020, Wuhan Tongji Hospital reported that an SARS-CoV-2-infected pregnant woman gave birth to a child who tested SARS-CoV-2-positive 36 h after birth; these results suggested the possibility of mother-to-child transmission. On Feb. 8, 2020 in Zhejiang, a pregnant woman with severe COVID-19 gave birth to a newborn who was negative on multiple subsequent nucleic acid virus tests for SARS-CoV-2. Nonetheless, a recent study revealed that fetal infection could be transmitted in late pregnancy (Chen HJ et al., [@B11]). These observations may relate to low expression of ACE2 among cells detected at the maternal--fetal interface (Zheng et al., [@B91]). Overall, there appears to be a minimal risk of fetal infection via known routes of vertical transmission.

Other potential routes of infection: Some researchers have speculated that SARS-CoV-2 could be transmitted through conjunctiva, although a recent study refuted this possibility. In this study, only one of the 67 patients with COVID-19 had conjunctivitis; the virus nucleic acid test of secretions from the conjunctival sac was negative (Zhou YY et al., [@B94]).

3.1.3 Population susceptibility

The population at large is generally susceptible with no predominance of a given sex or age. Among all known patients, those who are older (over 50 years old) accounted for 53.6% of the reported cases and children (\<10 years old) account for only 0.9%; there is a small male predominance at 51.4% (Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, [@B64]). Patients with underlying co-morbidities (including hypertension, diabetes, pre-existing respiratory infection, cardiovascular disease, and cancer) are more likely to succumb and undergo progression to the more severe forms of COVID-19 and also have a higher risk of developing complications (Guan et al., [@B27]; Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, [@B64]; Yang Y et al., [@B83]). In one study, 26% of infected subjects have at least one underlying co-morbidity (Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, [@B64]). Family members of COVID-19 patients as well as medical care providers are at high risk for infection due to more frequent contact with infected patients. Medical staff accounted for 29% of the COVID-19 patients admitted to the Zhongnan Hospital of Wuhan University between Jan. 1 and 28 of 2020 (Wang DW et al., [@B68]).

3.2. COVID-19 epidemic
----------------------

3.2.1 Dissemination process

On Dec. 26, 2019, Dr. Ji-xian ZHANG in the Hubei Hospital of Integrated Traditional Chinese and Western Medicine identified an elderly couple with pneumonia of unknown etiology, and subsequently found five patients with similar clinical presentations on the next day; most of these individuals reported exposure at the Huanan Seafood Market. On Dec. 29, 2019, she reported this issue to the Hubei Provincial Health and Health Committee (Fan et al., [@B21]). A retrospective analysis of these initial cases revealed that extensive human-to-human transmission of SARS-CoV-2 has taken place in Wuhan since mid-December 2019 (Li et al., [@B50]). COVID-19 rapidly expanded from the initial sporadic epidemic to a region-limited epidemic and now, a pandemic.

Sporadic epidemic: On Jan. 1, 2020, the Wuhan government announced the closure of the Huanan Seafood Market and strengthened preventive measures put in place at surrounding farmers' markets and public places in Wuhan. Prior to Jan. 1, the disease was mainly identified in sporadic epidemics or clusters among people in direct contact with the seafood market. More than half of the cases identified at that time presented with a history of exposure to Huanan Seafood Market (Huang et al., [@B33]).

Region-limited epidemic: After Jan. 1, 2020, only 8.6% of reported cases could be directly linked to the Huanan Seafood Market, suggesting that the transmission had shifted to the community. There was clear evidence of cluster transmission in multiple communities and families in Wuhan (Li et al., [@B50]; Xu Z et al., [@B80]; Zhu N et al., [@B95]). Because this unfortunately coincided with the Chinese Lunar New Year and a time of substantial travel, the epidemic spread quickly within Hubei Province and other areas of China.

Pandemic: On Jan. 13, 2020, the government of Thailand identified a Chinese visitor who was infected with SARS-CoV-2. Subsequent confirmed cases arose in many countries and regions, marking the beginning of a pandemic (Munster et al., [@B58]). At present, with the exception of Antarctica, confirmed cases have been identified in all continents of the globe. As of 10 a.m. (Central European Time (CET)) on Mar. 15, 2020, there are 153 717 confirmed cases worldwide with 81 048 of these cases in China (World Health Organization, [@B72]).

3.2.2 Spatial distribution

In China: As of Mar. 15, 2020, COVID-19 cases have been identified in 34 provincial regions in China. Hubei Province has the largest number of cases (67 794), which represents 84% of all COVID-19 cases in China. Most likely due to their geographical locations that are close to Hubei Province, 9605, 6899, and 6324 cases were reported in Henan, Hunan, and Anhui Provinces, respectively. Guangdong and Zhejiang Provinces have reported 11 346 and 5737 confirmed cases, respectively; they are thus ranked 2nd and 4th in the total number of COVID-19 cases among all the provinces in China (World Health Organization, [@B72]).

Globally: COVID-19 has reached global epidemic proportions; there have been many forecasts as to when the peak will be reached. Nan-shan ZHONG (Cyranoski, [@B17]) estimated that the COVID-19 epidemic would reach its peak at the end of February 2020, but others believe that the epidemic will peak sometime from mid-March to late May 2020. As of Mar. 15, 2020, COVID-19 has been reported in 144 countries/territories/areas across five continents. The Republic of Korea (8162 cases), Japan (780 cases), and Malaysia (238 cases) reported the most confirmed cases in Asia outside China. A total of 45 061 cases were reported in Europe, including Italy (21 157 cases), Spain (5753 cases), and France (4469 cases). In region of Americas, the United States of America (1678 cases), Canada (244 cases), and Brazil (121 cases) have each reported cases, as has Australia (Oceania; 249 cases) and Egypt (Africa; 93 case). In addition, a final total of 697 cases were confirmed on the Diamond Princess cruise ship (World Health Organization, [@B72]).

4. Government measures to contain COVID-19 in China
===================================================

On Jan. 20, 2020, the Chinese government identified COVID-19 as a Class B infectious disease and adopted preventive and containment measures ordinarily used for Class A infectious diseases. The efforts to contain COVID-19 in China followed the essential principles that included identifying and isolating the infectious sources and cutting off the transmission routes.

First, the Huanan Seafood Market, known to be the source of the initial outbreak, was closed and sterilized; all further wild animal transactions were prohibited. On Jan. 23, 2020, the Chinese government closed Wuhan City, an unprecedented and decisive step taken to prevent viral spread to other cities in China, as well as abroad. After the closure of Wuhan City, regular wards in all hospitals, as well as sports stadiums, convention centers, and other public buildings, were renovated into quarantine wards and medical resources nationwide, including medical staff, equipment, and diagnostic agents, were rapidly concentrated in Wuhan. The local government carried out a thorough and rigorous screening to identify all potential infected and infectious individuals and their contacts. Patients diagnosed with COVID-19 were admitted to hospitals or renovated provisional medical shelters, depending on the degree of disease severity at presentation; those whose disease progressed while in medical shelters were transferred to hospitals in a timely manner. All the aforementioned measures were enacted to ensure that all the patients were isolated and treated. The general population was instructed to take rigorous personal preventive measures including wearing masks in public places together with frequent hand washing and social distancing. The daily life of residents in Wuhan was ensured by allocation of adequate food supplies and other necessities by the central government.

China's centralized efforts to contain the epidemic have prevented further transmission of COVID-19; there has been a significant decline in newly identified and confirmed cases since Feb. 5, 2020. China's prevention and control strategies represent important experiences that may serve as inspiration for containment policies in other nations suffering the impact of this emerging infectious disease.

5. Clinical features
====================

Several published studies have documented the varied degrees of clinical severity of COVID-19 as shown in Table [1](#T1){ref-type="table"} (Chen NS et al., [@B13]; Guan et al., [@B27]; Huang et al., [@B33]; Wang DW et al., [@B68]; Xu XW et al., [@B79]; Yang XB et al., [@B82]; Young BE et al., [@B84]). The incubation period (initial infection to symptoms) ranges from 0 to 24 d, with an average of 5--7 d (Guan et al., [@B27]). Individuals of any age are susceptible to infection, including neonates and pregnant women. Most patients present with mild to moderate symptoms. The most common symptoms are fever, dry cough, fatigue; upper respiratory tract symptoms can include pharyngalgia, headaches, and myalgia. There is also one report describing patients with gastrointestinal symptoms, including abdominal pain and diarrhea in children and adolescents (Xu Z et al., [@B80]). In addition, asymptomatic patients have also been reported, although the frequency of this condition has not yet been determined. Approximately 20% of COVID-19 patients develop severe respiratory illness, with an overall case-fatality rate of about 2.3%. Patients with severe disease typically present with fever, dry cough, dyspnea, and bilateral pulmonary infiltrates on chest imaging. Complications of COVID-19 include ARDS, respiratory failure, liver injury, acute myocardial injury, acute kidney injury, septic shock, and even multiple organ failure. The risk factors for disease progression have not yet been established; however, preliminary evidence suggests that severe disease is more likely to take hold in individuals of older age, male sex, and in those with underlying co-morbidities. A study with 1099 confirmed COVID-19 patients was notable for the fact that about 23% had one or more underlying diseases, including chronic obstructive pulmonary disease (1.1%), hypertension (14.9%), diabetes (7.4%), coronary atherosclerotic heart disease (2.5%), and hepatitis B and liver cirrhosis (2.3%) (Guan et al., [@B27]). A national survey involving over 70 000 COVID-19 patients reported that more than 80% of the individuals who succumbed to the disease were older than 60 years of age and more than 75% had cardio-cerebral-vascular disease and/or diabetes. The milder forms of COVID-19 seem to be more commonplace in regions outside Wuhan; in a series of 62 patients in a cohort study carried out in Zhejiang Province of China, only one COVID-19 patient developed ARDS and none died in response to the disease (Xu XW et al., [@B79]).

###### 

Cohort and case-series studies that feature clinical aspects of COVID-19

  Study                  City, province, or country   Participant           Male^1^              Clinical presentation^1^                                                                                                     
  ---------------------- ---------------------------- --------------------- -------------------- -------------------------- ----------------------------------------- ------------ ---------- ---------- ---------- --------- ----
  Huang et al., [@B33]   Wuhan, China                 41                    30                   40                         18                                        31           26                               18        1
  (73.20%)               (97.60%)                     (43.90%)              (75.60%)             (63.40%)                   (55.0%)^\*^                               (2.6%)^\*^                                              
  Wang DW                Wuhan, China                 138                   75                   136                        96                                        82           97         24         48         43        17
  et al., 2020           (54.30%)                     (98.60%)              (69.60%)             (59.40%)                   (70.30%)                                  (17.40%)     (34.80%)   (31.10%)   (12.30%)             
  Chen NS                Wuhan, China                 99                    67                   82                                                                   81           35         5          11         31        3
  et al., 2020           (67.70%)                     (82.80%)              (81.80%)             (35.40%)                   (5.00%)                                   (11.10%)     (31.30%)   (3.00%)                         
  Guan et al., [@B27]    China                        1099                  640                  966                        419                                       744          902        153        163        204       95
  (58.20%)               (87.90%)                     (38.10%)              (67.70%)             (82.10%)                   (13.90%)                                  (14.80%)     (18.60%)   (8.60%)                         
  Xu XW et al., [@B79]   Zhejiang, China              62                    36                   48                         32                                        50           19                    32         2         3
  (58.10%)               (77.40%)                     (51.60%)              (80.60%)             (30.60%)                   (51.60%)                                  (3.20%)      (4.80%)                                    
  Young BE               Singapore                    18                    9                    13                                                                   15           7          11         4          2         3
  et al., 2020           (50.00%)                     (72.20%)              (83.30%)             (38.90%)                   (61.10%)                                  (22.20%)     (11.10%)   (16.70%)                        
  Yang XB                Wuhan, China                 52                    35                   51                         18                                        40           44                    6          33        2
  et al., 2020           (67.30%)                     (98.10%)              (34.60%)             (76.90%)                   (84.60%)                                  (11.50%)     (63.50%)   (3.80%)                         
                                                                                                                                                                                                                              
                                                                                                                                                                                                                              
  Study                  Age^2^(year)                 Incubation^3^(d)      Complication^1^      Sever case^1^              Death^1^                                                                                          
  ARDS                   Cardiac injury               Acute kidney injury   Acute liver injury   Septic shock               Failure of more than one organ (SOFA≥2)                                                           
                                                                                                                                                                                                                              
  Huang et al., [@B33]   49                           8                     12                   5                          3                                                      3                     13         6         
  (41--58)               (5--13)                      (29.30%)              (12.20%)             (7.30%)                    (7.30%)                                   (31.70%)     (14.60%)                                   
  Wang D et al., 2020    56                           7                     22                   16                         5                                                      11         36         36         6         
  (42--68)               (4--8)                       (15.90%)              (11.60%)             (3.60%)                    (7.90%)                                   (26.10%)     (26.10%)   (4.40%)                         
  Chen N et al., 2020    55.5                                               17                   0                          3                                                      4          11         29         11        
  (42.4--68.6)           (17.20%)                     (0.00%)               (3.00%)              (4.00%)                    (11.10%)                                  (29.30%)     (11.10%)                                   
  Guan et al., [@B27]    47                           3                     37                   11                         6                                                      7                     173        15        
  (35--58)               (0--24)                      (3.40%)               (1.00%)              (0.50%)                    (0.60%)                                   (15.70%)     (1.40%)                                    
  Xu XW et al., [@B79]   41                           4                     1                                                                                                                            1          0         
  (32--52)               (3--5)                       (1.60%)               (1.60%)              (0.00%)                                                                                                                      
  Young BE               47                           12                    2                    0                          0                                         3            0          2          2          0         
  et al., 2020           (31--73)                     (1--24)               (11.10%)             (0.00%)                    (0.00%)                                   (16.70%)     (0.00%)    (11.10%)   (11.10%)   (0.00%)   
  Yang XB                59.7±13.3                                          35                   12                         15                                        15                                 52         32        
  et al., 2020           (sever cases)                (67.30%)              (23.10%)             (28.80%)                   (28.80%)                                  (100.00%)    (61.50%)                                   

^1^ The values are expressed as number (percentage); ^2^ The values are expressed as median (IQR) or mean±standard deviation; ^3^ The values are expressed as median (IQR). ^\*^ The total number of participants is not 41 because some information was missing. IQR: interquartile range; ARDS: acute respiratory distress syndrome; SOFA: sequential organ failure assessment

Lymphopenia is frequently identified among COVID-19 patients; the total white blood cell count is generally within normal limits of slightly decreased in mild cases but increased in severe or critically ill patients. Indicators of systemic inflammation, including serum levels of ferritin and C-reactive protein (CRP) as well as erythrocyte sedimentation rate (ESR), can be elevated in association with high levels of circulating pro-inflammatory cytokines and chemokines. Likewise, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), troponin, and/or creatinine may be elevated in patients with extra-pulmonary systemic complications.

Findings on chest computed tomography (CT) are frequent, reaching nearly 100% in early reports and over 80% in a recent cohort of patients outside Wuhan. Several critical points with respect to the lung parenchyma and interstitial tissue have been observed that are directly linked to the stages and severity of the disease. Generally, early lesions were single or multiple and presented as limited patchy shadows with interstitial changes, typically located at in the peripheral lung fields just inside the pleura. Positive bronchus signs and thickening of the blood vessels can be detected. The lesions may progress in both number and scope and ultimately generate multiple ground glass opacities bilaterally, with or without minimal pleural effusion. In severe or critical illness, multi-lobular and diffuse infiltrates can be detected on chest CT; these can evolve rapidly to full lung consolidation.

6. Diagnosis and assessment of severity
=======================================

An epidemiological history should be taken for any individual presenting with symptoms suggesting COVID-19; this would include a history of recent travel to or residence in Hubei Province, notably in Wuhan and/or in other areas and communities affected by COVID-19; likewise, information should be carefully checked on close contact with confirmed or probable patients at home, work or health care facilities where hospital-associated cases have been reported in 14 d prior to symptom onset. A full and complete definitive diagnosis requires isolation of SARS-CoV-2, sequencing of the viral genome, or test of viral nucleic acid by polymerase chain reaction (PCR) in a specimen collected from the upper respiratory tract (nasopharyngeal and oropharyngeal swabs) and if possible, from the lower respiratory tract (sputum, tracheal aspirate, or bronchoalveolar lavage). Tests for other virus pathogens should be conducted simultaneously in order to generate a complete diagnosis.

Isolation of virus from a patient specimen is not routinely recommended because of concern for biosafety. Furthermore, presence of viral nucleic acid in stool has been reported (Xie et al., [@B75]), although these findings do not constitute a definitive diagnosis. Currently, the nucleic acid test is the most widely used diagnostic approach, but the sensitivity has not been clearly determined. An alternative diagnostic procedure that incorporated symptoms, epidemiological history, and chest CT was applied in Wuhan, given concerns regarding the sensitivity of the nucleic acid test. This diagnostic procedure, which involves no direct virologic evidence, is an effective provisional measure that can be used to identify potential cases in the shortest time possible in an area with a high concentration of cases. However, this methodology will inevitably lead to misdiagnosis.

As shown in Table [2](#T2){ref-type="table"}, the spectrum of disease severity can be categorized into patterns that include mild, moderate, severe, and critical illness, as per to the latest national protocol used for the diagnosis and treatment of COVID-19. The natural history of each pattern requires further clarification. For instance, it has not yet been determined what proportion of mild to moderate cases ultimately become severely or critically ill.

###### 

Criteria for assessing the severity of COVID-19

  Severity         Criteria
  ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mild             Minimal symptoms without pulmonary involvement in chest imaging studies
  Moderate         Fever and/or respiratory symptoms; multiple limited patchy shadows and interstitial changes in chest imaging
  Severe           Dyspnea with a respiratory rate of \>30 breaths per minute; resting oxygen saturation below 95% or arterial blood oxygen partial pressure/oxygen concentration ≤300 mmHg (1 mmHg=0.133 kPa); multi-lobular disease or lesion progression of \>50% within 48 h; sequential organ failure assessment (SOFA) of ≥2 points; pneumothorax and/or other clinical conditions requiring hospitalization
  Critically ill   Respiratory failure requiring mechanical ventilation; septic shock; additional organ failure

7. Management
=============

Currently, disease prevention and control, supportive care, and close monitoring are the essential cornerstone measures for population management of COVID-19. Severe or critically ill patients generally require oxygen therapy and intensive care as the disease frequently progresses to induce complications such as ARDS, respiratory failure, and septic shock. Despite all therapeutic efforts, the mortality rate of patients in an intensive care unit (ICU) setting remains at about 40%. In efforts to reduce mortality related to severe COVID-19, attempts have been made to design therapies that either limit virus replication or modulate the host immune response. Among these, treatment with Arbidol, a broad-spectrum antiviral drug approved for influenza, has been introduced in a cohort of patients admitted to the First Affiliated Hospital of Zhejiang University, Hangzhou, China (Xu KJ et al., [@B77]). Likewise, systemic glucocorticoids, although controversial, have been explored in a series of patients with mild disease; this modality was well tolerated and viral shedding was not prolonged (unpublished data). A combination of glucocorticoid together with the antiviral immunomodulatory agent, interferon-α (IFN-α), was also evaluated. Loutfy et al. ([@B53]) reported that glucocorticoids together with IFN-α can quickly reverse pulmonary imaging abnormalities and improve blood oxygen saturation in patients with SARS. Similarly, a blood purification treatment method known as Li's artificial liver has been reported to play a beneficial role in alleviating the cytokine storm and can reduce the complications including shock, hypoxemia, and acute respiratory distress in critically ill patients (Xu KJ et al., [@B77]).

8. Vaccine development and drugs in the pipeline for COVID-19
=============================================================

8.1. Vaccine development
------------------------

Vaccine development is a key strategy for preventing widespread viral infection and reducing morbidity and mortality. The novel virus SARS-CoV-2 was first isolated by Chinese scientists; the genome sequence is currently available to the public (Chan et al., [@B10]; Zhu N et al., [@B95]). These advances together with cooperation and open-source data make it possible to design multiple SARS-CoV-2 vaccine candidates.

Vaccines are typically divided into different types, including inactivated vaccines, live attenuated vaccines, vectored vaccines, nucleic acid-based vaccines, and recombinant subunit vaccines (Gao et al., [@B25]).

8.1.1 Inactivated vaccines and live attenuated vaccines

Inactivated and live attenuated vaccines are based on the antigenicity of killed and weakened versions of the virus, respectively. Inactivated vaccines may include whole inactivated virus particles, specific components derived from the virus or toxoids that are chemically modified to destroy their pathogenicity (Stauffer et al., [@B65]). China National Biotec Group already has some inactivated vaccine candidates available for testing; their immunogenicity and efficacy are currently under evaluation in experimental animals. Live attenuated vaccines are derived from microbial agents that have been weakened via physical, chemical, or biological means under laboratory conditions (Badgett et al., [@B5]). Codagenix (USA) has formed a collaboration with Serum Institute of India in order to develop a rationally designed live attenuated vaccine against SARS-CoV-2 that is synthesized by viral codon deoptimization.

8.1.2 Vectored vaccines

Vectored vaccines are those utilizing other viruses as vectors for SARS-CoV-2 proteins; among such vaccine vectors currently under exploration are the chimeric parainfluenza virus, rabies virus, modified vaccinia Ankara (MVA) virus, vesicular stomatitis virus (VSV), and adenovirus. Scientists of Rocky Mountain Laboratories (USA) and Oxford University (UK) have been collaborating to develop a chimpanzee adenovirus-vectored vaccine against SARS-CoV-2. Likewise, Zydus Cadila, an India-based pharmaceutical company, has launched a program to develop a vectored vaccine for the novel coronavirus SARS-CoV-2 using live attenuated recombinant measles virus (rMV); rMV is generated by reverse genetics and expresses codon-optimized proteins of SARS-CoV-2 in order to induce specific neutralizing antibodies.

8.1.3 Nucleic acid-based vaccines

Injection of nucleic acid constructs that can express viral or bacterial genes can result in the activation of both humoral and cellular immune responses. Zydus Cadila has a program to develop a DNA vaccine against the major viral membrane S protein responsible for the cell entry of SARS-CoV-2. After the plasmid DNA is introduced into host cells, it will be translated into the viral protein and elicit immune responses. This provides protection from infection and can lead to viral clearance. Inovio Pharmaceuticals (USA) is currently collaborating with Beijing Advaccine Biotechnology Company (China) to advance the development of INO-4800 as a vaccine candidate targeting SARS-CoV-2. This vaccine is currently undergoing preclinical testing; clinical product manufacturing is in progress for a planned parallel phase I clinical trial in China. Applied DNA Sciences' subsidiary (New York, USA), LineaRx (New York, USA), and Takis Biotech (Rome, Italy) are developing a linear DNA vaccine for the SARS-CoV-2, using PCR-based DNA manufacturing technology. Additionally, Moderna (USA) is also developing a messenger RNA (mRNA) vaccine against SARS-CoV-2 encoding for the viral S protein, in collaboration with the National Institutes of Health (USA).

8.1.4 Recombinant subunit vaccines

Recombinant subunit vaccines are composed of several microbial components produced in a heterologous expression systems (Plotkin, [@B60]). Compared with inactivated vaccines and live attenuated vaccines, one of the most important advantages of subunit vaccines is their significant safety profile as they contain only noninfectious recombinant proteins or synthetic peptides, with no infectious viruses (Zhang et al., [@B86]). The S protein of SARS-CoV-2 plays a key role in receptor binding and membrane fusion; as such, vaccines based on the S protein may be able to induce antibodies to block virus binding and fusion and thus neutralize virus infection (Huang et al., [@B33]; Ji et al., [@B36]). The S protein is one of the most important antigenic components of the coronavirus structural proteins as it can evoke both host immune responses and neutralizing antibodies. It has therefore been selected as a promising target for a vaccine (He and Jiang, [@B29]). Clover Biopharmaceuticals (Chengdu, China) has initiated the development of a recombinant subunit vaccine for SARS-CoV-2 that utilizes S protein subunit-trimer antigens.

8.2. Drugs in the pipeline for COVID-19
---------------------------------------

So far there are no specific antiviral measures available to treat COVID-19. Most of the typical options guiding drug manufacture take years of development and are obviously inadequate for the ongoing outbreak. In this situation, studies are often conducted on compassionate use of unproven therapies and clinical trial approvals expedited.

In spite of our limited knowledge, there are several treatment options that could be pursued as first-line therapy for COVID-19. These modalities could be tested rapidly on patients currently diagnosed with SARS-CoV-2 infection.

8.2.1 Neutralizing antibodies targeting virus S protein

ACE2 has been identified as a cellular entry receptor of SARS-CoV-2, similar to that identified for SARS-CoV (Zhou P et al., [@B92]). SARS-CoV-2 entry starts with the S protein binding to ACE2 on the cell surface, after which the viral nucleocapsid is delivered into the cell prior to virus replication. The S protein is involved in receptor recognition as well as virus attachment and entry, both of which are attractive targets for the development of drugs to treat COVID-19. Neutralizing antibodies that target the S protein of SARS-CoV-2 may provide temporary, passive immunity to the disease (Zhao et al., [@B88]). The full genome sequence of SARS-CoV-2 (GenBank: MN908947.3) was clarified and disclosed to the public shortly after the pandemic originated in Wuhan, China. This allows scientists to perform gene synthesis in order to express the S protein as an immunogen (Chan et al., [@B10]). CR3022 and CR3014 developed by Crucell (the Netherlands) are human monoclonal antibodies (mAbs) that can neutralize the original SARS-CoV. These mAbs block the interaction between S protein and its cellular receptor ACE2 and thus completely prevent inflammatory pathology in the lungs of SARS-CoV-infected animal models (ter Meulen et al., [@B66]). Considering that the novel virus SARS-CoV-2 has high sequence similarity to the SARS-CoV virus, these two antibodies may be promising and might be evaluated for the treatment for COVID-19.

8.2.2 Inhibitors of ACE2

Given the critical role of ACE2 in the process of virus infection, ACE2 inhibitors may have anti-SARS-CoV-2 activity. Thousands of compounds, biologics, and traditional Chinese medicines from databases were screened. Results from these methods suggest that azathioprine, andrographis, urtica, sambucus, astragalus, valproic acid, butyrate, and epoxomicin may be effective strategies toward the development of anti-COVID-19 therapy (Cui QH et al., [@B16]).

8.2.3 Oligonucleotides against SARS-CoV-2 RNA genome

Modalities that target the virus RNA genome, including small interfering RNA (siRNA) and/or antisense oligonucleotides, might be another therapeutic option (Leonard and Schaffer, [@B45]; Watts and Corey, [@B70]). However, the appropriate RNA sequence targets of SARS-CoV-2 remain unknown and delivery of oligonucleotides to the lung is also a challenge. As such, gene therapy can be fully applicable for the design of treatments in the current outbreak.

8.2.4 Repurposing of currently available antiviral drugs

Small molecule drugs that have already been approved as antiviral (or other) medications may be candidates for COVID-19 treatment. Antivirals typically target viruses at different stages of infection and replication (Li and de Clercq, [@B49]). Viral polymerases and proteases are popular targets for antiviral regimens (Patick and Potts, [@B59]; Asselah et al., [@B4]; Lou et al., [@B52]). Pilot clinical studies have already been performed with the goal of repurposing antiviral drugs.

There are initial positive reports suggesting that the human immunodeficiency virus (HIV) protease inhibitors, lopinavir and ritonavir, have some clinical efficacy against SARS-CoV-2. These are currently undergoing evaluation in phase III clinical trials (NCT 04252274, NCT04251871, NCT04255017, ChiCTR 2000029539) (Chu et al., [@B14]; Sheahan et al., [@B63]). According to the preliminary experiments, darunavir, an anti-HIV drug that targets the viral protease, promoted significant inhibition of SARS-CoV-2 replication. The efficacy and safety of darunavir are planned for an evaluation of this drug together with the licensed anti-HIV drug, cobicistat, for the treatment of COVID-19 in a phase III clinical trial (NCT 04252274).

Arbidol (umifenovir), which has been approved for the treatment of influenza in Russia and China, is effective in vitro against a variety of coronaviruses including SARS-CoV-2 (Chu et al., [@B14]). As such, arbidol is currently provided to COVID-19 patients as empirical therapy and in phase IV clinical trials (NCT 04260594, NCT04254874, NCT04255017). Another anti-influenza medication favipiravir, an inhibitor of RNA-dependent RNA polymerase (RdRp), is also under consideration for randomized clinical trials for COVID-19 (ChiCTR2000029544, ChiCTR2000029600) (Li et al., [@B50]; Lu et al., [@B54]). Given the available knowledge on the safety profiles and efficacy against closely related viruses, existing antiviral agents are potentially helpful short-term strategies to combat SARS-CoV-2.

Remdesivir (Gilead), which is a nucleotide analog prodrug, was originally developed as a drug candidate for use in Ebola virus infection (phase I) (Agostini et al., [@B1]; Brown et al., [@B7]; Mulangu et al., [@B57]). Remdesivir showed positive efficacy against MERS in preclinical models and was administered to the first US case of COVID-19 on a compassionate use basis (Sheahan et al., [@B63]). Remdesivir is currently under evaluation in hospitalized adult patients with mild to moderate SARS-CoV-2 infections in a phase III trial in China (Wang M et al., [@B69]).

Chloroquine is another promising therapeutic candidate and has been used widely as a treatment for malaria and infections with amoebae. Chloroquine may have antiviral activity via its capacity to increase the endosomal pH and thereby inhibits viral fusion events. Other reports suggested that chloroquine could interfere with the glycosylation of cellular receptors of SARS-CoV and would be highly effective at controlling the progression of SARS-CoV-2 infection. Chloroquine showed encouraging anti-SARS-CoV-2 profile in early clinical trials (Wang M et al., [@B69]).

8.2.5 Convalescent patient serum

Patients who have recovered from the SARS-CoV-2 infection will develop a polyclonal immune response to viral antigens. These polyclonal antibodies may neutralize virus and prevent further infection in the recovered host (Arabi et al., [@B3]; Zhao et al., [@B89]; Al-Tawfiq et al., [@B2]). Therefore, convalescent patient serum may be a potentially effective tool for treating and preventing further disease related to this outbreak. It was reported that serum from a convalescent SARS patient inhibited SARS-S protein-driven virus entry and reduced SARS-CoV-2 virus entry (Hoffmann et al., [@B31]). Passive transfer of antibodies from convalescent patient serum is currently under consideration for the treatment of COVID-19 patients with severe disease.

8.2.6 Traditional Chinese medicine and herbal remedies

Several kinds of traditional Chinese medicine have documented antiviral and antibacterial properties and been reported as beneficial to the immune system (Jin et al., [@B38]). According to the advice and guideline for the diagnosis and treatment of pneumonia due to SARS-CoV-2 infection, traditional Chinese medicines would be tailored to match the individual patient signs and symptoms. For patients in different stages of disease, the recommended prescriptions include various ingredients known to practitioners of traditional Chinese medicine as well as Chinese patent medicines such as injections of Xiyanping and Xuebijing, which have been also used for clinical treatment.

Rapid identification and deployment of effective interventions against SARS-CoV-2 infection represent a major challenge. This outbreak has emphasized the urgent need for constant and ongoing efforts to develop vaccines and broad-spectrum antiviral agents that broadly target coronavirus pathogens. With the ongoing efforts to prevent the virus spread and develop helpful drug and vaccine strategies, we hope that the outbreak will subside shortly.

9. Conclusions
==============

Since the outbreak of the COVID-19 epidemic, critical departments have actively responded and coordinated their efforts under the direction of the Chinese government, and medical personnel have risen to the difficulties regardless of personal danger. Although the number of individuals diagnosed with the disease is still rising and has not yet reached its peak, the overall epidemic in China has shown a downward trend. At present, comprehensive surveillance remains critical so as to isolate the source of infection, eliminate the routes of transmission, accelerate diagnosis and treatment of suspected cases, and actively research and take measures to deal with the risks of infection and transmission that may result from the scheduled return to work and school.

Because of the unrelenting efforts of scientific researchers, we have a clear picture of the structure and genetic make-up of the SARS-CoV-2 (Xu XT et al., [@B78]; Zhou P et al., [@B92]) as well as its interactions with a characterized receptor (Yan RH et al., [@B81]), its host source (Lam et al., [@B42]; Zhou P et al., [@B93]; Zhu N et al., [@B95]), epidemiological characteristics (Bao et al., [@B6]; Favre et al., [@B23]; Huang et al., [@B33]), and histopathological changes that take place in lung tissue in response to infection (Xu Z et al., [@B80]). There are still many urgent questions that need to be answered. Will the virus SARS-CoV-2 mutate to produce new strains? Will COVID-19 persist in our lives and in our hospitals? In addition to the bats (Zhou P et al., [@B93]; Wu et al., [@B74]) and pangolins (Lam et al., [@B42]), are there any additional primary and/or intermediate hosts for this virus? What can we do to improve isolation and disinfection? Further research is needed so that we will have a clearer understanding of diagnosis and treatment, prognosis, as well as efforts toward vaccine and drug development. Any solution will be of great significance for overcoming COVID-19 and for preparations for any recurrence.
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